乳腺癌新辅助化疗中MCM7和C—erbB-2的表达及其临床意义

目的：探讨乳腺癌新辅助化疗前后MCM7和C—erbB-2蛋白的表达状况，分析其与化疗疗效的关系。方法：采用免疫组化法检测55例乳腺癌新辅助化疗前后标本中MCM7和C—erbB-2的表达。结果：新辅助化疗有效率为76．4％。化疗前MCM7蛋白阳性表达显著高于化疗后（P〈0．01），而化疗前后C—erbB-2蛋白阳性表达差异无显著性（P〉0．05）。化疗有效组（42例）MCM7蛋白阳性表达显著高于无效组（13例）（P〈0．01），而化疗有效组C—erbB-2蛋白阳性表达显著低于无效组（P〈0．01）。结论：ET方案新辅助化疗有较好的疗效，可能通过抑制MCM7蛋白表达来阻止乳腺癌细胞的增殖。MCM7高表达，C—erbB-2阴性者化疗更为敏感，二者可作为临床指导乳腺癌化疗并预测化疗敏感性的分子生物学指标。

Expression of MCM7 and C -erbB -2 in neoadjuvant chemotherapy of breast cancer and its clinical significance

Objctive ：To study the expressions of MCM7 and C -erbB -2 before and after neoadjuvant chem -otherapy in breast cancer patients, analyze their relationship with response to neoadjuvant chemotherapy and its clinical significance. Methods ： The expressions of MCM7 and C - erbB - 2 before and after neoadjuvant chemotherapy were examined by immunohistochemistry in 55 cases of breast cancer. Results： The overall response rate to neoadjurant chemotherapy was 76.4%. The positive expression of MCM7 before neoadjuvant chemotherapy was significantly higher than that after neoadjuvant chemotherapy（ P 〈 0.01 ）, but there was no significant difference in the expression of C - erbB - 2 before and after neoadjuvant chemotherapy （ P 〉 0.05 ）. The positive expression of MCM7 in the group of response to neoadjuvant chemotherapy was significantly higher than that of no response to neoadjuvant chemotherapy（ P 〈 0.01 ）. The positive expression of C -erbB -2 in the group of response to neoadjuvant chemotherapy was significantly lower than that of no response to neoadjuvant chemotherapy （ P 〈 0. 01 ）. Conclusion： bleoadjuvant chemotherapy with ET regimen is effective, and it may inhibit the proliferatation of breast cancer cell by downregulation of the expression of MCM7. Patients with MCM7 high expression and negative C - erbB - 2 were more likely to respond to chemotherapy. The expression of MCM7 and C - erbB - 2 as biological markers could be a guide for chemotherapy and prediction for its response to chemotherapy in breast cancer.